TY - JOUR
T1 - Nanocarriers assisted siRNA gene therapy for the management of cardiovascular disorders
AU - Maheshwari, Rahul
AU - Tekade, Muktika
AU - Sharma, Piyoosh A.
AU - Tekade, Rakesh Kumar
N1 - Publisher Copyright:
© 2015 Bentham Science Publishers.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Cardiovascular diseases (CVDs), primarily myocardial infarction (MI), atherosclerosis, hypertension and congestive heart failure symbolize the foremost cause of death in almost all parts of the world. Besides the traditional therapeutic approaches for the management of CVDs, newer innovative strategies are also emerging on the horizon. Recently, gene silencing via small interfering RNA (siRNA) is one of the hot topics amongst various strategies involved in the management of CVDs. The siRNA mechanism involves natural catalytic processes to silence pathological genes that are overexpressed in a particular disease. Also the versatility of gene expression by siRNA deciphers a prospective tactic to down-regulate diseases associated gene, protein or receptor existing on a specific disease target. This article reviews the application of siRNA against CVDs with special emphasis on gene targets in combination with delivery systems such as cationic hydrogels, polyplexes, peptides, liposomes and dendrimers.
AB - Cardiovascular diseases (CVDs), primarily myocardial infarction (MI), atherosclerosis, hypertension and congestive heart failure symbolize the foremost cause of death in almost all parts of the world. Besides the traditional therapeutic approaches for the management of CVDs, newer innovative strategies are also emerging on the horizon. Recently, gene silencing via small interfering RNA (siRNA) is one of the hot topics amongst various strategies involved in the management of CVDs. The siRNA mechanism involves natural catalytic processes to silence pathological genes that are overexpressed in a particular disease. Also the versatility of gene expression by siRNA deciphers a prospective tactic to down-regulate diseases associated gene, protein or receptor existing on a specific disease target. This article reviews the application of siRNA against CVDs with special emphasis on gene targets in combination with delivery systems such as cationic hydrogels, polyplexes, peptides, liposomes and dendrimers.
KW - Cardiovascular disorders
KW - Myocardial infarction
KW - RNAi
KW - SiRNA
UR - https://www.scopus.com/pages/publications/84946051633
U2 - 10.2174/138161282130151007150300
DO - 10.2174/138161282130151007150300
M3 - Article
C2 - 26471319
AN - SCOPUS:84946051633
SN - 1381-6128
VL - 21
SP - 4427
EP - 4440
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 30
ER -